Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.68 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738303 | 1.00 | ALDH1A1 (0.73) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| Hydrochloric Acid SCHEMBL16825204 | 0.98 | ALDH1A1 (0.71) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| SCHEMBL9417737 | 0.98 | SIGMAR1 (0.72) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| Hydrochloric Acid SCHEMBL11467058 | 0.96 | SIGMAR1 (0.70) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| SCHEMBL23851311 | 0.94 | SIGMAR1 (0.72) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| SCHEMBL11360607 | 0.90 | SIGMAR1 (0.85) | ALDH1A1KDM4ESIGMAR1CYP2A13PLA2G1B | |
| SCHEMBL11194277 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4EPOLBRAB9AHTT | |
| SCHEMBL29941203 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| SCHEMBL17523584 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 | |
| SCHEMBL2095997 | 0.83 | SIGMAR1 (0.58) | ALDH1A1KDM4EPOLBSIGMAR1CYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| EP-1003489-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | Adolor Corporation (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999003455-A1 | FILM-FORMING COMPOSITIONS OF ANTIHYPERALGESIC OPIATES AND METHOD OF TREATING HYPERALGESIC AND PRURITIC CONDITIONS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2014-03-27 | — | — | US | disclosed |
| WO-2012162814-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | MCMASTER UNIVERSITY (CA) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-8080549-B2 | Endothelin receptor antagonists | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | ALDH1A1 1862/4885KDM4E 1873/4885POLB 2713/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | ALDH1A1 1243/4885KDM4E 2746/4885POLB 981/4885 |
| US-20140088069-A1 | NOVEL ANTIBACTERIAL COMBINATION THERAPY | NCBP2, TPX2, GTPBP4 | ALDH1A1 4803/4885KDM4E 4184/4885POLB 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.